14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
⏸️ WAIT FOR STABILIZATION: MRNA is down 12.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Valuation Analysis: MRNA is currently trading at $195.00, which is considered oversold relative to its 30-day fair value range of $204.80 to $244.10.
Technical Outlook: Technically, MRNA is in a strong uptrend. The price is currently testing key support at $189.98. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MRNA scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $164.53. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$204.80 -
$244.10
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
Trading Range & Key Levels
30-Day Trading Range
$204.80 -
$244.10
Current vs Trading Range
OVERSOLD
Support Level$189.98
Resistance Level$280.80
Current TrendStrong Uptrend
Technical data as of
Nov 20, 2026
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZONSpot $215.27 · IV 83.7%
bloggers & journalists: you are free to use our charts with attribution.
Reddit & Retail Trader Sentiment (MRNA)
Bearish
3 Retail Mentions
Reddit / WSB Comments
1
Bearish
Retail Stream Volume
2 msgs
24h retail stream
Last Tracked
Nov 21, 2026
Daily AI digest
AI Retail Discussion Summary:
Moderna stock faces potential losses if its cancer vaccine with Merck underperforms, with the share price currently trading at a high valuation. The setback would not significantly impact sales, as the vaccine is not yet approved.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.